Study finds new drug may hold promise for hospitalized heart failure patients
Hospitalized heart failure patients given an investigational drug had improved symptoms and other clinical benefits including fewer deaths, than those given standard of care plus a placebo, according to late-breaking clinical trial research presented at the American Heart Association's Scientific Sessions 2012.
The full manuscript for RELAXin in Acute Heart Failure (RELAX-AHF) Trial, is published in Lancet.
Compared to those given a placebo, patients given serelaxin experienced a significant reduction in heart failure symptoms including a 20 percent reduction in a measure of shortness of breath. Additionally, patients receiving serelaxin:
- experienced over 45 percent fewer episodes of worsening heart failure symptoms during hospitalization;
- Spent almost half a day less time in the intensive care units;
- Had almost a full day shorter hospital stay.
Serelaxin did not reduce rehospitalizations among heart failure patients.
Serelaxin is a peptide hormone or a chain of molecules that relax blood vessels and improve blood flow to organs, potentially protecting them from acute injury.
"Current therapy for acute heart failure has remained unchanged for decades," said John R. Teerlink, M.D., co-principal investigator of the trial and professor of medicine at the University of California in San Francisco. "Acute heart failure is a major public health problem and an expensive one due to repeat hospitalizations since patients' worsening symptoms keep coming back."
"Our findings suggest serelaxin holds promise as the first evidence-based therapy for acute heart failure to substantially improve patients' symptoms and clinical outcomes, including death," said Teerlink, who is director of the heart failure program at the San Francisco Veterans Affairs Medical Center.
The multicenter phase III, conducted October 2009-February 2012, included 1,161 patients at 96 sites in 11 countries.
Researchers randomly assigned patients to receive 30 mcg/kg per day of serelaxin or a placebo through a 48-hour intravenous infusion. Patients received the medication within 16 hours of hospitalization for heart failure-related symptoms of shortness of breath with evidence of decline in kidney function. They also received standard therapy with diuretics to help flush fluid or congestion from the body and reduce swelling.
Nearly two-thirds of the patients were men, most were Caucasian and average age was 72 years. Most patients had multiple diseases: 87 percent had high blood pressure; 53 percent high cholesterol; 52 percent ischemic heart disease; 52 percent atrial fibrillation; 48 percent diabetes; and 14 percent had suffered a stroke.
"We are pleased with the results," said Marco Metra, M.D., co-principal investigator of the trial, professor of cardiology at the University of Brescia and head of the Cardiology Institute of the Civil Hospital of Brescia, Italy. "While we did not see a reduction in rehospitalizations in this trial, the significant reductions in worsening of heart failure and death are encouraging signals that we can change the course of this devastating disease."
Journal reference: The Lancet
Provided by American Heart Association
- Hormone Relaxine helps treat heart failure: study Mar 30, 2009 | not rated yet | 0
- Atrial fibrillation linked to increased hospitalization in heart failure patients Jul 06, 2009 | not rated yet | 0
- New mathematical model more accurately diagnoses acute heart failure in emergency rooms Oct 15, 2009 | not rated yet | 0
- Study shows short-term kidney failure in heart patients may not be as detrimental Jul 01, 2010 | not rated yet | 0
- Implantable monitor may help in managing diastolic heart failure Dec 11, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Question of reflection and transmission of TEM wave in normal incidenc
30 minutes ago Suppose TEM wave in +z normal to a boundary on xy plane at z=0. We know *E* & *H* are tangential to the boundary. Let ##\vec E_i=\hat x E##, be the...
the rudyak-krasnolutski effective potencial
1 hour ago Hi ... anyone now how to calculate or the formula of the rudyak-krasnolutski EFFECTIVE potencial ? the effective potencial includes the angular...
Normal force for a lever model
2 hours ago My model is a lever on a table top. One arm is horizontal on the table, while the other arm is raised at an angle alpha. I'm assuming the weight of...
gravity is std. therefore can we rate a 'mass at height' by watts?
8 hours ago For example.... wind turbines are primarily listed by their wattage (1.5MW etc.) Presumably their output is varied according to rotational speed, so...
Calculating on-axis elements of a solenoid
20 hours ago I wanted to mention that this solenoid has many winds over many layers. The thickness of the windings is 2.4 inches coming off of the engineering...
latitude & longitude & air pressure
21 hours ago Hi there, I have a peculiar question. Imagine that you are in a earth position, obtained by google, that gives you the latitude and longitude....
- More from Physics Forums - Classical Physics
More news stories
UCLA researchers examining outcomes for advanced heart-failure patients over the past two decades have found that, coinciding with the increased availability and use of new therapies, overall mortality has decreased and sudden ...
Cardiology 1 hour ago | not rated yet | 0
22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...
Cardiology 5 hours ago | not rated yet | 0
Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.
Cardiology May 22, 2013 | not rated yet | 0
Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...
Cardiology May 22, 2013 | not rated yet | 0
Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...
Cardiology May 22, 2013 | 5 / 5 (1) | 0
Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...
28 minutes ago | not rated yet | 0 |
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
55 minutes ago | not rated yet | 0 |
Finnish researchers unveiled new data Thursday to link the Pandemrix flu vaccine to a higher risk of the sleeping disorder narcolepsy in adults.
28 minutes ago | not rated yet | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
18 minutes ago | not rated yet | 0
The Senate has overwhelmingly rejected an amendment allowing states to require labeling of genetically modified foods.
8 minutes ago | not rated yet | 0
A second child has contracted polio in a restive Pakistani tribal region near the Afghan border after the Taliban banned vaccinations there nearly a year ago, a UN official said Thursday.
48 minutes ago | not rated yet | 0